Bellicum Pharmaceuticals (BLCM) PT Lowered to $25 at Citi Following Rimiducid Activation Switch
Tweet Send to a Friend
Citi lowered its price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) to $25.00 (from $27.00) while maintaining a Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
